Mona Salimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mona Salimi has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Amir Amanzadeh
National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
11 shared publications Mohsen Amini
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Teharn, Iran
8 shared publicationsRaheleh Tahmasvand
Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran
8 shared publications- Ali Almasirad
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
6 shared publications Saeed Irian
Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
6 shared publicationsHassan Hadadzadeh
Isfahan University of Technology
5 shared publications
Latest Publications
- 26 October 2025
- Published by Elsevier
- Vol. 96, 181-215
Theranostic application of extracellular vesicles in breast cancer
- 26 October 2025
- Published by Elsevier
- Vol. 96, 181-215
Theranostic application of extracellular vesicles in breast cancer
- 14 February 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 157, 108267
Discovery of a new hydrazone-oxamide hybrid capable of inducing necroptotic cell death in triple negative breast cancer cells
- 14 February 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 157, 108267
Discovery of a new hydrazone-oxamide hybrid capable of inducing necroptotic cell death in triple negative breast cancer cells
- Open Access
- 6 April 2024
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (2) , 200800
Harnessing exosomes as a platform for drug delivery in breast cancer: A systematic review for in vivo and in vitro studies
- 6 April 2024
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (2) , 200800
Open AccessHarnessing exosomes as a platform for drug delivery in breast cancer: A systematic review for in vivo and in vitro studies
- Open Access
- 1 March 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (2) , 132-139
Polyethylene Glycol-Mediated Exosome Isolation: A Method for Exosomal RNA Analysis
Background: Exosomal RNAs (ExoRNAs) offer valuable insights into their cellular origin. ExoRNA studies were faced with challenges in obtaining sufficient amounts of high-quality RNA. Herein, we aimed to compare three traditional exosome isolation methods to introduce an appropriate strategy to extract RNA from cancer-derived exosomes for further RNA analysis. Methods: ...
- 1 March 2024
- Published by Apex Publishing in Iranian Biomedical Journal
- Vol. 28 (2) , 132-139
Open AccessPolyethylene Glycol-Mediated Exosome Isolation: A Method for Exosomal RNA Analysis
Background: Exosomal RNAs (ExoRNAs) offer valuable insights into their cellular origin. ExoRNA studies were faced with challenges in obtaining sufficient amounts of high-quality RNA. Herein, we aimed to compare three traditional exosome isolation methods to introduce an appropriate strategy to extract RNA from cancer-derived exosomes for further RNA analysis. Methods: ...
- 19 January 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (7) , 5119-5129
In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer
Triple-negative breast cancer is a subtype of breast cancer with poor clinical outcome, and currently, no effective targeted therapies are available. Since cancer develops owing to deregulation of apoptosis, employing therapeutic strategies with the ability to target the molecules involved in apoptosis induction would provide a valid approach to hinder tumor progression. Hydrazide-hydrazones and oxamide molecules are the subject of intense studies due to their anticancer effects via apoptosis induction. In the present study, we attempted to elucidate the mechanism of action of a synthesized compound (compound A) in inducing cell death. Annexin/PI and Western blotting analyses, DAPI staining, mitochondrial membrane potential probe, and flow cytometry were applied for the in vitro evaluations. 4T1 syngeneic mouse model and immunohistochemistry were used for the in vivo assessments. Compound A caused cell death by inducing apoptosis in MDA-MB-231 cells in a mitochondrial-dependent manner at high concentrations after 72 h of incubation. Compound A also impeded tumor growth in a 4T1 syngeneic mouse model as evidenced by hematoxylin and eosin staining of the tumors. Furthermore, it significantly diminished the expression of pro-caspase-3, Ki67, and CD31 markers in the tumor sections. Conclusively, this study for the first time reports the anti-cancer efficacy of compound A in both in vitro and in vivo models and its potential in the treatment of triple-negative breast cancer.
- 19 January 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (7) , 5119-5129
In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer
Triple-negative breast cancer is a subtype of breast cancer with poor clinical outcome, and currently, no effective targeted therapies are available. Since cancer develops owing to deregulation of apoptosis, employing therapeutic strategies with the ability to target the molecules involved in apoptosis induction would provide a valid approach to hinder tumor progression. Hydrazide-hydrazones and oxamide molecules are the subject of intense studies due to their anticancer effects via apoptosis induction. In the present study, we attempted to elucidate the mechanism of action of a synthesized compound (compound A) in inducing cell death. Annexin/PI and Western blotting analyses, DAPI staining, mitochondrial membrane potential probe, and flow cytometry were applied for the in vitro evaluations. 4T1 syngeneic mouse model and immunohistochemistry were used for the in vivo assessments. Compound A caused cell death by inducing apoptosis in MDA-MB-231 cells in a mitochondrial-dependent manner at high concentrations after 72 h of incubation. Compound A also impeded tumor growth in a 4T1 syngeneic mouse model as evidenced by hematoxylin and eosin staining of the tumors. Furthermore, it significantly diminished the expression of pro-caspase-3, Ki67, and CD31 markers in the tumor sections. Conclusively, this study for the first time reports the anti-cancer efficacy of compound A in both in vitro and in vivo models and its potential in the treatment of triple-negative breast cancer.
- Open Access
- 24 December 2023
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 22 (1)
Biological Activity of Novel Pyrrole Derivatives as Antioxidant Agents Against 6-OHDA Induced Neurotoxicity in PC12 Cells
Background: Neuroinflammation and oxidative stress are critical factors involved in the pathogenesis of Parkinson's disease (PD), the second most common progressive neurodegenerative disease. Additionally, lipid peroxidation end products contribute to inflammatory responses by activating pro-inflammatory genes. Lipid peroxidation occurs as a result of either the overproduction of intracellular reactive oxygen species (ROS) or the reaction of cyclooxygenases (COXs). Objectives: In this study, we examined the role of 1,5-diaryl pyrrole derivatives against the neurotoxic effects of 6-hydroxydopamine (6-OHDA) in a cellular model of PD. Methods: PC12 cells were pre-treated with compounds 2-(4-chlorophenyl)-5-methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrrole (A), 2-(4-chlorophenyl)-1-(4-methoxyphenyl)-5-methyl-1H-pyrrole (B), and 1-(2-chlorophenyl)-2-(4-chlorophenyl)-5-methyl-1H-pyrrole (C), respectively, 24 h before exposure to 6-OHDA. We conducted various assays, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT), ROS, and lipid peroxidation assays, Hoechst staining, Annexin V/PI, Western blotting analysis and ELISA method, to assess the neuroprotective effects of pyrrole derivatives on 6-OHDA-induced neurotoxicity. Results: Our results demonstrated that apoptosis induction was inhibited by controlling the lipid peroxidation process in the in vitro model following pre-treatment with compounds A, B, and, somehow, C. Furthermore, compounds A and C likely act by suppressing the COX-2/PGE2 pathway, a mechanism not attributed to compound B. Conclusions: These findings suggest that the novel synthetic pyrrolic derivatives may be considered promising neuroprotective agents that can potentially prevent the progression of PD.
- 24 December 2023
- Published by Brieflands in Iranian Journal of Pharmaceutical Research
- Vol. 22 (1)
Open AccessBiological Activity of Novel Pyrrole Derivatives as Antioxidant Agents Against 6-OHDA Induced Neurotoxicity in PC12 Cells
Background: Neuroinflammation and oxidative stress are critical factors involved in the pathogenesis of Parkinson's disease (PD), the second most common progressive neurodegenerative disease. Additionally, lipid peroxidation end products contribute to inflammatory responses by activating pro-inflammatory genes. Lipid peroxidation occurs as a result of either the overproduction of intracellular reactive oxygen species (ROS) or the reaction of cyclooxygenases (COXs). Objectives: In this study, we examined the role of 1,5-diaryl pyrrole derivatives against the neurotoxic effects of 6-hydroxydopamine (6-OHDA) in a cellular model of PD. Methods: PC12 cells were pre-treated with compounds 2-(4-chlorophenyl)-5-methyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrrole (A), 2-(4-chlorophenyl)-1-(4-methoxyphenyl)-5-methyl-1H-pyrrole (B), and 1-(2-chlorophenyl)-2-(4-chlorophenyl)-5-methyl-1H-pyrrole (C), respectively, 24 h before exposure to 6-OHDA. We conducted various assays, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT), ROS, and lipid peroxidation assays, Hoechst staining, Annexin V/PI, Western blotting analysis and ELISA method, to assess the neuroprotective effects of pyrrole derivatives on 6-OHDA-induced neurotoxicity. Results: Our results demonstrated that apoptosis induction was inhibited by controlling the lipid peroxidation process in the in vitro model following pre-treatment with compounds A, B, and, somehow, C. Furthermore, compounds A and C likely act by suppressing the COX-2/PGE2 pathway, a mechanism not attributed to compound B. Conclusions: These findings suggest that the novel synthetic pyrrolic derivatives may be considered promising neuroprotective agents that can potentially prevent the progression of PD.
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S429
NOVEL SYNTHETIC 1,5-DIARYL PYRROLE DERIVATIVES PROTECT PC12 CELLS AGAINST 6-OHDA- INDUCED NEUROTOXICITY
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S429
Open AccessNOVEL SYNTHETIC 1,5-DIARYL PYRROLE DERIVATIVES PROTECT PC12 CELLS AGAINST 6-OHDA- INDUCED NEUROTOXICITY
- Open Access
- 15 May 2023
- Published by Springer Nature in Research Square
Development of the potential synthesized compound to cause triple negative breast cancer cell death through intrinsic apoptosis mechanism
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor clinical outcome, and currently no effective targeted therapies are available. Since cancer develops owing to deregulation of apoptosis, employing therapeutic strategies with ability to target the molecules involved in apoptosis induction, would provide a valid approach to hinder tumor progression. Hydrazide-hydrazones and oxamide molecules are the subject of intense studies due to their anticancer effects via apoptosis induction. In the present study, we attempted to elucidate the mechanism of action of a synthesized compound (compound A) and understand if the cell death occurs through inducing the apoptosis. These properties were investigated using the, annexin/PI and Western blotting analyses, DAPI staining, and mitochondrial membrane potential probe. Compound A also impeded the tumor growth in a 4T1 syngeneic mouse model as evidenced by hematoxylin and eosin staining of the tumors. Apart from that, it significantly diminished the expression of pro-caspase-3, Ki67 and CD31 markers in the tumor sections. Conclusively, this study for the first time reports the anti-cancer efficacy of compound A in both in vitro and in vivo models, which may serve as a potent candidate in triple negative breast cancer (TNBC) treatment.
- 15 May 2023
- Published by Springer Nature in Research Square
Open AccessDevelopment of the potential synthesized compound to cause triple negative breast cancer cell death through intrinsic apoptosis mechanism
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with poor clinical outcome, and currently no effective targeted therapies are available. Since cancer develops owing to deregulation of apoptosis, employing therapeutic strategies with ability to target the molecules involved in apoptosis induction, would provide a valid approach to hinder tumor progression. Hydrazide-hydrazones and oxamide molecules are the subject of intense studies due to their anticancer effects via apoptosis induction. In the present study, we attempted to elucidate the mechanism of action of a synthesized compound (compound A) and understand if the cell death occurs through inducing the apoptosis. These properties were investigated using the, annexin/PI and Western blotting analyses, DAPI staining, and mitochondrial membrane potential probe. Compound A also impeded the tumor growth in a 4T1 syngeneic mouse model as evidenced by hematoxylin and eosin staining of the tumors. Apart from that, it significantly diminished the expression of pro-caspase-3, Ki67 and CD31 markers in the tumor sections. Conclusively, this study for the first time reports the anti-cancer efficacy of compound A in both in vitro and in vivo models, which may serve as a potent candidate in triple negative breast cancer (TNBC) treatment.
- Open Access
- 1 November 2022
- Published by Springer Nature in BMC Chemistry
- Vol. 16 (1) , 1-15
Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity
Background: Compounds possessing urea/thiourea moiety have a wide range of biological properties including anticancer activity. On the other hand, taking advantage of the low toxicity and structural diversity of hydrazone derivatives, they are presently being considered for designing chemical compounds with hydrazone moiety in the field of cancer treatment. With this in mind, a series of novel ureido/thioureido derivatives possessing a hydrazone moiety bearing nitro and chloro substituents (4a–4i) have been designed, synthesized, characterized and evaluated for their in vitro cytotoxic effect on HT-29 human colon carcinoma and HepG2 hepatocarcinoma cell lines. Results: Two compounds (4c and 4e) having the chloro phenylurea group hybridized with phenyl hydrazone bearing nitro or chloro moieties demonstrated potent anticancer effect with the IC50 values between 2.2 and 4.8 µM at 72 h. The mechanism of action of compound 4c was revealed in hepatocellular carcinoma cells as an inducer of apoptosis in a caspase-independent pathway. Conclusion: Taken together, the current work presented compound 4c as a potential lead compound in developing future hepatocellular carcinoma chemotherapy drugs. Methods: The compounds were synthesized and then characterized by physical and spectral data (FT-IR, 1H-NMR, 13C-NMR, Mass). The anticancer activity was assessed using MTT assay, flowcytometry, annexin-V, DAPI staining and Western blot analysis. Graphical
- 1 November 2022
- Published by Springer Nature in BMC Chemistry
- Vol. 16 (1) , 1-15
Open AccessDesign and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity
Background: Compounds possessing urea/thiourea moiety have a wide range of biological properties including anticancer activity. On the other hand, taking advantage of the low toxicity and structural diversity of hydrazone derivatives, they are presently being considered for designing chemical compounds with hydrazone moiety in the field of cancer treatment. With this in mind, a series of novel ureido/thioureido derivatives possessing a hydrazone moiety bearing nitro and chloro substituents (4a–4i) have been designed, synthesized, characterized and evaluated for their in vitro cytotoxic effect on HT-29 human colon carcinoma and HepG2 hepatocarcinoma cell lines. Results: Two compounds (4c and 4e) having the chloro phenylurea group hybridized with phenyl hydrazone bearing nitro or chloro moieties demonstrated potent anticancer effect with the IC50 values between 2.2 and 4.8 µM at 72 h. The mechanism of action of compound 4c was revealed in hepatocellular carcinoma cells as an inducer of apoptosis in a caspase-independent pathway. Conclusion: Taken together, the current work presented compound 4c as a potential lead compound in developing future hepatocellular carcinoma chemotherapy drugs. Methods: The compounds were synthesized and then characterized by physical and spectral data (FT-IR, 1H-NMR, 13C-NMR, Mass). The anticancer activity was assessed using MTT assay, flowcytometry, annexin-V, DAPI staining and Western blot analysis. Graphical
- Open Access
- 1 May 2022
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 13 (3) , 295-304
Protein Kinase C Involvement in Neuroprotective Effects of Thymol and Carvacrol Against Toxicity Induced by Amyloid-β in Rat Hippocampal Neurons
Introduction: We have reported that thymol and carvacrol can improve cognitive abilities in Alzheimer Disease (AD) rat models. However, the mechanism of their action is not yet fully understood. Recently, our in vitro results suggested that PC12 cell death induced by Aβ25-35 can be protected by thymol and carvacrol via Protein Kinase C (PKC) and Reactive Oxygen Species (ROS) pathways. So, we hypothesize that the mechanisms of thymol and carvacrol in improving the learning impairment in the AD rat model may be related to their effects on PKC. So, the activity of PKC and protein expression levels of PKCα were examined in the hippocampal cells of the AD rat model. Methods: To examine the thymol and carvacrol effects, we performed a behavioral test in AD rat models induced by Aβ25–35 neurotoxicity. To access the underlying mechanism of the protective effects, western blotting was performed with antibodies against PKCα. We also measured the PKC activity assay by Elisa. Histopathological studies were carried out in the hippocampus with Hematoxylin and Eosin (H&E) staining. Results: The escape latency increased in Aβ-received rats compared to the control group, and thymol and carvacrol reversed this deficit. Furthermore, these compounds could enhance the PKC activity and increase the PKCα expression ratio. Moreover, H&E staining showed that Aβ caused shrinkage of the CA1 pyramidal neurons. However, thymol and carvacrol treatments could prevent this effect of Aβ peptides. Conclusion: This study suggests that Amyloid-Beta (Aβ) results in memory decline and histochemical disturbances in the hippocampus. Moreover, these results revealed that thymol and carvacrol could have protective effects on cognition in AD-like models via PKC activation.
- 1 May 2022
- Published by Negah Scientific Publisher in Basic and Clinical Neuroscience Journal
- Vol. 13 (3) , 295-304
Open AccessProtein Kinase C Involvement in Neuroprotective Effects of Thymol and Carvacrol Against Toxicity Induced by Amyloid-β in Rat Hippocampal Neurons
Introduction: We have reported that thymol and carvacrol can improve cognitive abilities in Alzheimer Disease (AD) rat models. However, the mechanism of their action is not yet fully understood. Recently, our in vitro results suggested that PC12 cell death induced by Aβ25-35 can be protected by thymol and carvacrol via Protein Kinase C (PKC) and Reactive Oxygen Species (ROS) pathways. So, we hypothesize that the mechanisms of thymol and carvacrol in improving the learning impairment in the AD rat model may be related to their effects on PKC. So, the activity of PKC and protein expression levels of PKCα were examined in the hippocampal cells of the AD rat model. Methods: To examine the thymol and carvacrol effects, we performed a behavioral test in AD rat models induced by Aβ25–35 neurotoxicity. To access the underlying mechanism of the protective effects, western blotting was performed with antibodies against PKCα. We also measured the PKC activity assay by Elisa. Histopathological studies were carried out in the hippocampus with Hematoxylin and Eosin (H&E) staining. Results: The escape latency increased in Aβ-received rats compared to the control group, and thymol and carvacrol reversed this deficit. Furthermore, these compounds could enhance the PKC activity and increase the PKCα expression ratio. Moreover, H&E staining showed that Aβ caused shrinkage of the CA1 pyramidal neurons. However, thymol and carvacrol treatments could prevent this effect of Aβ peptides. Conclusion: This study suggests that Amyloid-Beta (Aβ) results in memory decline and histochemical disturbances in the hippocampus. Moreover, these results revealed that thymol and carvacrol could have protective effects on cognition in AD-like models via PKC activation.